The Transgenic Mouse/ES Cell Shared Resource has been in existence since 1993 and has received continuous funding from the NCI since the Vanderbilt-lngram Cancer Center (VICC) was awarded its first Cancer Center Support Grant in 1995. At the time of the last competitive renewal, this shared resource received an "Outstanding" rating. This resource provides gene targeting, DNA pronuclear microinjections, ES cell microinjections, assisted reproduction and both sperm and embryo cryopreservation services to members of the VICC. These services are essential for the generation, maintenance, and long-term storage of germline-altered mice. The resource continues to function in a multidisciplinary manner and has undergone several significant changes since the last competitive evaluation that have enabled it to continue to provide gene targeting and microinjection services at reasonable prices, to develop several new services, and to improve both its quality control and data management strategies. The Transgenic Mouse/ES Cell Shared Resource continues to offer services that remain in high demand and vital to the generation of new mouse models of cancer and other diseases. This will be critical as the gene-specific information from genome-wide cancer studies is translated to mouse models of human cancer. Moreover, the technology base that this resource supports is expected to be important in allowing Vanderbilt investigators to adapt to using of human pluripotent stem cells in the future.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Vanderbilt University Medical Center
United States
Zip Code
Han, Ying; Signorello, Lisa B; Strom, Sara S et al. (2015) Generalizability of established prostate cancer risk variants in men of African ancestry. Int J Cancer 136:1210-7
Sanders, Melinda E; Schuyler, Peggy A; Simpson, Jean F et al. (2015) Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up. Mod Pathol 28:662-9
Chaturvedi, R; de Sablet, T; Asim, M et al. (2015) Increased Helicobacter pylori-associated gastric cancer risk in the Andean region of Colombia is mediated by spermine oxidase. Oncogene 34:3429-40
Vilgelm, Anna E; Pawlikowski, Jeff S; Liu, Yan et al. (2015) Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. Cancer Res 75:181-93
Wei, Jinxiong; Noto, Jennifer M; Zaika, Elena et al. (2015) Bacterial CagA protein induces degradation of p53 protein in a p14ARF-dependent manner. Gut 64:1040-8
Carrillo, A M; Bouska, A; Arrate, M P et al. (2015) Mdmx promotes genomic instability independent of p53 and Mdm2. Oncogene 34:846-56
Balko, Justin M; Giltnane, Jennifer M; Wang, Kai et al. (2014) Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov 4:232-45
Weeke, Peter; Mosley, Jonathan D; Hanna, David et al. (2014) Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndrome. J Am Coll Cardiol 63:1430-7
Cheng, Feixiong; Jia, Peilin; Wang, Quan et al. (2014) Studying tumorigenesis through network evolution and somatic mutational perturbations in the cancer interactome. Mol Biol Evol 31:2156-69
Peng, Dun-Fa; Hu, Tian-Ling; Soutto, Mohammed et al. (2014) Loss of glutathione peroxidase 7 promotes TNF-?-induced NF-?B activation in Barrett's carcinogenesis. Carcinogenesis 35:1620-8

Showing the most recent 10 out of 1594 publications